Bringing vaccines to chronic disease


Bringing Vaccines
to chronic disease


Bringing Vaccines
to chronic disease


A humanized osteopontin mouse model and its application in immunometabolic obesity studies.

Grün NG, Zeyda K, Moreno-Viedma V, Strohmeier K, Staffler G, Zeyda M, Stulnig TM.
Transl Res. 2016 (accepted).

Common dysregulated pathways in obese adipose tissue and atherosclerosis.

Moreno-Viedma V, Amor M, Sarabi A, Bilban M, Staffler G, Zeyda M, Stulnig TM.
Cardiovascular Diabetology. 2016 (accepted).

Identification of matrix metalloproteinase-12 as a candidate molecule for prevention and treatment of cardiometabolic disease.

Amor M, Moreno-Viedma V, Sarabi A, Grün NG, Itariu B, Leitner L, Steiner I, Bilban M, Kodama K, Butte AJ, Staffler G, Zeyda M, Stulnig TM.
Molecular Medicine. 2016 (accepted).

Osteopontin Affects Macrophage Polarization Promoting Endocytic but not Inflammatory Properties.

Schuch K, Wanko B, Ambroz K, Castelo-Rosa A, Moreno-Viedma V, Grüun G.V, Leitner L, Staffler G, Zeyda M, and Stulnig T.M.
Obesity. 2016 (accepted).

Inhibition of Cellular Adhesion by Immunological Targeting of Osteopontin Neoepitopes Generated through Matrix Metalloproteinase and Thrombin Cleavage.

Jürets A, Le Bras M, Staffler G, Stein G, Leitner L, Neuhofer A, Tardelli M, Turkof E, Zeyda M, Stulnig TM.
PLoS One. 2016 Feb 3;11(2).

Active immunization against complement factor C5a: a new therapeutic approach for Alzheimer’s disease.

Landlinger C, Oberleitner L, Gruber P, Noiges B, Yatsyk K, Santic R, Mandler M, Staffler G.
J Neuroinflammation. 2015 Aug 16;12:150.

Active immunization therapies for Parkinson’s disease and multiple system atrophy.

Schneeberger A, Tierney L, Mandler M.
Mov Disord. 2015 Aug 11.

Immunological blockade of adipocyte inflammation caused by increased matrix metalloproteinase-cleaved osteopontin in obesity.

Leitner L, Schuch K, Jürets A, Itariu BK, Keck M, Grablowitz V, Aszmann OC, Prager G, Staffler G, Zeyda M, Stulnig TM.
Obesity (Silver Spring). 2015 Apr;23(4):779-85.

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.

Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E.
Mol Neurodegener. 2015 Mar 19;10(1):10.

Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines.

Mandler M, Santic R, Gruber P, Cinar Y, Pichler D, Funke SA, Willbold D, Schneeberger A, Schmidt W, Mattner F.
PLoS One. 2015 Jan 22;10(1).

Peptide-based anti-PCSK9 vaccines – an approach for long-term LDLc management.

Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairhofer A, Lührs P, Schneeberger A, von Bonin A, Mattner F, Schmidt W, Staffler G.
PLoS One. 2014 Dec 4;9(12).

Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer’s disease.

Mandler M, Walker L, Santic R, Hanson P, Upadhaya AR, Colloby SJ, Morris CM, Thal DR, Thomas AJ, Schneeberger A, Attems J.
Acta Neuropathol. 2014 Jul;128(1):67-79.

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials.

Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E.
Acta Neuropathol. 2014;127(6):861-79.

An accelerated mouse model for atherosclerosis and adipose tissue inflammation.

Neuhofer A, Wernly B, Leitner L, Sarabi A, Sommer NG, Staffler G, Zeyda M, Stulnig TM.
Cardiovasc Diabetol. 2014 Jan 17;13:23. doi: 10.1186/1475-2840-13-23.

Vaccination for Parkinson’s disease.

Schneeberger A, Mandler M, Mattner F, Schmidt W.
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S11-3.

Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer’s disease and in AβPP transgenic mice using a novel monoclonal antibody.

Mandler M, Rockenstein E, Ubhi K, Hansen L, Adame A, Michael S, Galasko D, Santic R, Mattner F, Masliah E.
J Alzheimers Dis. 2012;28(4):783-94.

AFFITOME® technology in neurodegenerative diseases: the doubling advantage.

Schneeberger A, Mandler M, Mattner F, Schmidt W.
Hum Vaccin. 2010 Nov;6(11):948-52.

Development of AFFITOPE vaccines for Alzheimer’s disease (AD)-from concept to clinical testing.

Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W.
J Nutr Health Aging. 2009 Mar;13(3):264-7.

Kommentare sind geschlossen.